Abstract: Hyperglycemia is common in patients hospitalized for critical illness, trauma or after surgery, and is associated with increased morbidity and mortality. The Glucosafe system was developed to provide decision support for control of stress hyperglycemia in the intensive care unit. Glucosafe uses an insulin-glucose model to predict blood glucose (BG) concentrations, based on the patients previous and current insulin infusion, nutrition, and BG measurements. As endogenous insulin production is dependent on BG in a negative feedback loop, a pancreas model of endogenous insulin production was incorporated into the Glucosafe system. We investigated the stability of the feedback loop by calculating the loop gain of the model at different steadystate BG concentrations and insulin sensitivities. We also examining the models BG oscillations, after an initial perturbation, at different insulin sensitivities. Results show that both steady-state BG and insulin sensitivity influences the size of the loop gain. The largest loop gain (6.9) occurs at an insulin sensitivity of 1.2 and a BG of 5.5 mmol/l, where the BG perturbation resulted is damped oscillations of BG and endogenous insulin production. The BG dependent endogenous insulin production did not result in an unstable Glucosafe insulin-glucose model, although it did introduce damped oscillations in BG and insulin production during rapid increases in BG. It may be prudent to investigate if these oscillations can be decreased, possibly via the construction of a pancreas model which includes both a phase-1 and phase-2 response.
INTRODUCTION
Hyperglycemia is common in patients hospitalized for critical illness, trauma or after surgery, and has been associated with increased morbidity and mortality (Falciglia et al., 2009; Corathers and Falciglia, 2011) . Intensive insulin therapy has been tested as a means to achieve glycemic control (Van den Berghe et al., 2001; Krinsley, 2004) and the Glucosafe system was developed to provide decision support for control of stress hyperglycemia in the intensive care unit (ICU). The Glucosafe system advises on nutrition and insulin.
Glucosafe uses an insulin-glucose model to predict blood Glucose (BG) concentrations, based on the patients previous and current insulin infusion, nutrition, and BG measurements (Pielmeier et al., 2012 ). The Glucosafe model uses an endogenous insulin production model that produces constant rates of insulin, regardless of the patients BG concentration. However experimental studies have shown that the endogenous insulin production is not fixed but dependent on BG, with the relationship between BG concentration and endogenous insulin production being a sigmoid shape (Kronenberg et al., 2008) .
A variable insulin production model (pancreas model) has previously been added to the Glucosafe model to investigate if such a model would improve Glucosafe's ability to predict BG . The shape of the sigmoid function in the pancreas model was optimized using measurements from 12 critically ill patients in a neuro-ortho-trauma intensive care unit. While the inclusion of a pancreas model did improve the predictive capability of Glucosafe the improvement was marginal and could not justify its continued inclusion, likely due to the patients having such high BG concentrations that there was little difference between the constant and variable insulin production models. (Pielmeier et al., 2012) If Glucosafe is to be usable for less hyperglycemic patients, a pancreas model should be included. However if the insulin production becomes dependent on BG, the insulin-glucose model contains a negative feedback loop. In any system, a feedback loop with a loop gain larger than 1, has the potential to make the system unstable resulting in oscillations. The potential instability of a system can be assessed by determining the loop gain and in linear systems the stability can be determined by applying the Nyquist stability criterion. However as the Glucosafe model is non-linear, the stability cannot be assessed by use of the Nyquist stability criterion (Nyquist, 1932) but can be assessed by examining the oscillations occuring from an initial perturbation of the BG (post-perturbation oscillations).
In this paper we will evaluate the stability of the glucoseinsulin model in the Glucosafe system by determining the loop gain and post-perturbation BG oscillations of the model. 
METHODS

The Glucosafe Model
A diagram of the Glucosafe model is shown in Fig. 1 . Glucosafe models plasma insulin (I) and peripheral insulin (Q) concentrations from the endogenous production (U ) and exogenous infusions (P ) of insulin and the removal of insulin by the kidneys and by insulin degradation in the liver and peripheral tissue. The insulin sensitivity (s) scales the effect of insulin on hepatic removal and peripheral absorption of glucose. The insulin sensitivity is a dimensionless parameter normalized to lie between zero and one, where values below one indicate insulin resistance. The blood glucose concentration (BG) is modeled from insulindependent and insulin-independent removal and glucose from nutrition and intravenous infusions (Pielmeier et al., 2010) . Details of the model and equations can be found in appendix A.
The Pancreas Model
The pancreas model is a function with sigmoid shape that describes the rate of endogenous insulin production as a non-linear dependency of the blood glucose concentration (Kronenberg et al., 2008) . The model curve is shaped by the following equation and is shown in Fig. 2 :
where U (t) is the endogenous insulin production and ep min and ep max are the minimum and maximum obtainable U (t), respectively. BG(t) is the blood glucose concentration at a given time, BG half is the blood glucose at which the change in the slope of the function changes from increasing to decreasing, and S is the slope of the function at BG half . The shape of the curve was previously optimized to the following values; ep min = -1.9 mU/min, ep max = 39 mU/min, S = 1.8, and BG half = 5.6 mmol/l, using data using data from critically ill patients (Pielmeier et al., Fig. 2 . The sigmoid curve representing the endogenous insulin production depending on blood glucose concentration.
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). With this model the endogenous insulin production is dependent on the BG through a negative feedback loop. An increase in BG results in increasing endogenous insulin production that counteracts the rise in BG.
Loop Gain
The stability of the pancreas model was analyzed by calculating the loop gain of the feedback loop. A loop gain larger than 1 shows that the model has the potential to become unstable and can result in oscillations in BG and endogenous insulin production.
The loop gain was calculated in the following manner:
(1) The endogenous insulin production (U (t)) was simulated at a specific steady state BG. (2) A new endogenous production rate (U (t) + ) was calculated with = U (t)/10. (3) The new endogenous insulin production rate was fixed and a new simulation of the steady-state BG was performed. (4) The increased insulin production (U (t)+ ) resulted in a lower steady state BG. The endogenous production that would have resulted from this BG if the pancreas model was used was then calculated (U (t) + δ), and the value of δ was deduced. (5) The loop gain was then calculated as:
Loop gain = |δ/ |.
The loop gain was calculated for steady state BG concentrations of 3.0 mmol/l to 10 mmol/l in steps of 0.5 mmol/l, for three different levels of insulin sensitivity (s). An insulin sensitivity of 0.3 which is often seen in critically ill patients, 1.0 representing normal insulin response, and 1.2 to investigate how dependent on insulin sensitivity, the stability is. The steady state BG concentrations were obtained by using either insulin infusions or intravenous glucose infusions.
RESULTS
The calculated loop gains for the combinations of steady state BG and insulin sensitivity are shown in Table 1 .
The results show that both steady state BG and insulin sensitivity influences the size of the loop gain. The largest loop gain (6.9) occurs at an insulin sensitivity of 1.2 and a BG of 5.5 mmol/l. Fig. 3 shows that the loop gain increases as insulin sensitivity increases and decreases as BG becomes lower or higher that 5.5-6 mmol/l.
As a loop gain larger than 1 indicates a potential for instability, the BG and endogenous insulin production was examined for oscillations. The largest loop gain occurred at a steady state BG of 5.5 -6 mmol/l and as such this should be where the model is least stable. For each of the three insulin sensitivities the post-perturbation oscillations were examined. The impulse was a rapid 1 mmol/l increase in BG and the following changes in BG and endogenous insulin production registered. The resulting damped oscillations in BG and endogenous insulin production, for insulin sensitivities 0.3 and 1.0, are shown in Fig. 4 . Results of the post-perturbation oscillation test show that a rapid increase in BG induces oscillations but that the oscillations die out. The BG oscillations are below 0.1 mmol/l after two hours with an insulin sensitivity of 0.3, an after four hours for an insulin sensitivity of 1.0. For an insulin sensitivity of 1.2 it took six hours before the oscillation amplitude was below 0.1 mmol/l.
DISCUSSION
From the results it is clear to see that the Glucosafe model has the potential to become unstable when the pancreas model feedback loop is included, as evident from the large loop gains obtained. The loop gain is clearly affected by the insulin sensitivity as the size of the loop gains decrease as insulin sensitivity decreases. This seems reasonable as the decrease in insulin sensitivity equates to less effect from the insulin and BG is thus less affected by a change in insulin production.
The loop gain also dependent on BG concentration with the biggest loop gain values observed at 5.5-6 mmol/l. This also seems reasonable as the sigmoid function of the pancreas model has the largest slope at 5.6 mmol/l and thus the largest change in insulin production relative to a change in BG. As BG increases or decreases from 5.6 mmol/l the change in insulin production relative to BG change decreases, and at high BG concentrations insulin saturation also have an effect.
Due to the non-linearity of the Glucosafe model, the stability could not be determined using the Nyquist stability criterion but was instead examined by perturbing the BG and observing the post-perturbation oscillations. The post-perturbation oscillations for BG and endogenous insulin insulin production shows that the model is not inherently unstable as the oscillations are damped. The time it takes for the oscillations to die out however may be problematic as this may affect the predictive capabilities of Glucosafe.
In conclusion the introduction of a variable endogenous insulin production model into the Glucosafe insulin-glucose model did not result in an unstable model, although it did however introduce damped oscillations in BG and endogenous insulin production during rapid increases in BG. It may be prudent to investigate if these oscillations can be decreased, possibly via the construction of a pancreas model which includes both a phase-1 and a phase-2 response. (Pielmeier et al., 2010 ). An illustration of the model can be seen in Fig. 1 and the nomenclature for the variables and parameters can be found in Table A. 1.
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Model equations:
Changes in plasma and peripheral insulin concentrations:
Plasma/peripheral insulin diffusion constant:
Peripheral insulin clearance rate:
Insulin removal from plasma:
Endogenous insulin: IF patient is type 1 diabetic THEN U (t) = 0 mU /min ELSE
Insulin action on glucose uptake:
Glucose gut absorption:
IF N (t) > 8.65 mmol /kg THEN e(t) = 0.03245 mmol /kg·min·m gut ELSE e(t) = (−4.33 · 10 −4 kg /mmol·min · N (t)
Hepatic balance: GLUT 1 and GLUT 3 mediated glucose uptake mmol/kg/l P GLU T 4 GLUT 4 mediated glucose uptake mmol/kg/l J 1+3 GLUT 1 and GLUT 3 maximal uptake rate 0.0093 mmol/kg/min J 4 GLUT 4 maximal uptake rate 0.0848 mmol/kg/min
Combined GLUT 1 and GLUT 3 carrier affinity 1.5 mmol/l K M 4 GLUT 4 carrier affinity 5 mmol/l V BG Glucose distribution volume l E Endogenous glucose balance mmol/kg/min z Glucose absorption rate for parenteral nutrition mmol/kg/min Renal glucose clearance:
Where f(.) is a moving average function describing the transition from reabsorption to excretion (K Rave, 2006) .
Peripheral glucose uptake:
P GLU T 1+3 (t) = J 1+3 BG(t) (BG(t) + K M 1+3 ) (A.16) P GLU T 4 (t) = J 4 BG(t) (BG(t) + K M 4 ) a(t) (A.17)
Endogenous glucose balance:
V BG = BM · 0.19 l /kg (A.18) E(t) = H(t) − R(t) − P GLU T 4 (t) − P GLU T 1+3 (t) (A.19) dBG dt = (e(t) + z(t) + E(t)) BM V BG (A.20)
The C-peptide/insulin kinetics parameters; k 1 , A BSA , V P , and V Q are calculated using the method presented by (Cauter et al., 1992) , 
